| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2025 | BCRX Biocryst Pharmaceuticals Inc | Barnes Alane P70 | Chief Legal Officer | Sell | 161,680 | $7.21 | $1,164,966.64 | -12.5% | +10.7% | - | |
| Dec 2, 2025 | VRNO Verano Holdings Corp. | Kalesnik Laura Marie | See Remarks | Sell | 5,850 | $0.95 | $5,557.50 | -1.6% | - | - | |
| Dec 2, 2025 | VRNO Verano Holdings Corp. | Spreckman David | Chief Marketing Officer | Sell | 4,903 | $0.95 | $4,657.85 | -2.0% | - | - | |
| Dec 2, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 8,000 | $481.61 | $3,852,845.94 | -39.6% | +8.4% | - | |
| Dec 2, 2025 | VRNO Verano Holdings Corp. | McDermott Edward Aloysious III | Chief Operating Officer | Sell | 3,451 | $0.95 | $3,278.45 | -1.3% | - | - | |
| Dec 2, 2025 | VRNO Verano Holdings Corp. | Miles Aaron Nathaniel | Chief Investment Officer | Sell | 5,018 | $0.95 | $4,767.10 | -1.5% | - | - | |
| Dec 1, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L64 | Chief Medical Officer | Sell | 6,580 | $14.35 | $94,418.39 | -3.6% | +7.4% | - | |
| Dec 1, 2025 | LQDA Liquidia Corp | Boyle Dana | Chief Accounting Officer | Sell | 303 | $32.19 | $9,753.57 | -0.2% | -3.5% | - | |
| Dec 1, 2025 | UTHR United Therapeutics Corp | Edgemond James45 | CFO And Treasurer | Sell | 21,000 | $479.99 | $10,079,695.58 | -17.5% | +7.1% | - | |
| Dec 1, 2025 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 4,000 | $29.30 | $117,200.00 | -5.7% | +4.6% | - | |
| Dec 1, 2025 | LQDA Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | Sell | 221 | $32.19 | $7,113.99 | -0.2% | -3.5% | - | |
| Dec 1, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 22,500 | $479.91 | $10,798,079.12 | -29.0% | +7.1% | - | |
| Dec 1, 2025 | LQDA Liquidia Corp | Schundler Russell59 | General Counsel | Sell | 1,072 | $32.19 | $34,507.68 | -0.2% | -3.5% | - | |
| Dec 1, 2025 | LQDA Liquidia Corp | Kaseta Michael58 | CFO And COO | Sell | 1,166 | $32.19 | $37,533.54 | -0.3% | -3.5% | - | |
| Dec 1, 2025 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 831 | $32.19 | $26,749.89 | -0.5% | -3.5% | - | |
| Dec 1, 2025 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 693 | $32.19 | $22,307.67 | -0.4% | -3.5% | - | |
| Dec 1, 2025 | PBH Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Senior VP Operations | Sell | 1,000 | $60.00 | $60,000.00 | -1.2% | +14.4% | - | |
| Dec 1, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 7,040 | $42.10 | $296,376.26 | -11.0% | +34.0% | - | |
| Nov 28, 2025 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 5,970 | $151.74 | $905,880.64 | -11.7% | -14.1% | - | |
| Nov 28, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 8,000 | $486.34 | $3,890,753.95 | -48.3% | +3.8% | - | |
| Nov 26, 2025 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 11,000 | $486.06 | $5,346,701.20 | -4.2% | -3.1% | - | |
| Nov 26, 2025 | JNJ Johnson & Johnson | Morikis John G64 | Director | Buy | 1,250 | $206.15 | $257,687.50 | +208.9% | +18.7% | - | |
| Nov 26, 2025 | JNJ Johnson & Johnson | Johnson & Johnson59 | 10% Owner | Sell | 6,337 | $10.03 | $63,560.11 | -0.2% | +18.7% | - | |
| Nov 26, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 200 | $42.89 | $8,578.00 | -0.9% | +2.3% | - | |
| Nov 26, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Mignone Roberto | Director | Sell | 50,000 | $26.03 | $1,301,505.00 | -10.1% | +28.9% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.